Lei Zhao

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Topics

Combination Therapy

Squamous Cell Carcinoma

Top Venues

Cancer medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
XinLei Ai, PengXin Zhang, XinMin Xie, Bo Qiu, Yujia Zhu, Lei Zhao, Mian Xi, YingJia Wu, SuPing Guo, JinYu Guo, FangJie Liu, DaQuan Wang, NaiBin Chen, QianWen He, YongHong Hu, MengZhong Liu, ZhaoXia Ding, Hui Liu
Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059). Cancer medicine (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Yu-Xian Yang, Yu-Zhen Zheng, Tian-Tian Gao, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Jun-Ye Wang, Shu-Nan Qi, Yong Yang, Lei Zhao
Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. Cancer medicine 11 (20) (2022)
Shiliang Liu, Liling Luo, Lei Zhao, Yujia Zhu, Hui Liu, Qiaoqiao Li, Ling Cai, Yonghong Hu, Bo Qiu, Li Zhang, JingXian Shen, Yadi Yang, Mengzhong Liu, Mian Xi
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nature communications 12 (1) (2021)
Yang-Xun Pan, Mian Xi, Yi-Zhen Fu, Dan-Dan Hu, Jun-Cheng Wang, Shi-Liang Liu, Jin-Bin Chen, Li Xu, Zhong-Guo Zhou, Meng-Zhong Liu, Min-Shan Chen, Lei Zhao, Yao-Jun Zhang
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. Cancers 11 (8) (2019)
Lu-Jun Shen, Mian Xi, Lei Zhao, Xuhui Zhang, Xiuchen Wang, Zhimei Huang, Qi-Feng Chen, Tianqi Zhang, Jingxian Shen, Mengzhong Liu, Jinhua Huang
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers 10 (12) (2018)